Hepatitis C Drugs Combined with Antiarrhythmic Drug can Cause Serious Slowing of Heart Rate
Patients treating hepatitis C with Harvoni (ledipasvir/sofosbuvir) or Sovaldi (sofosbuvir) in conjunction with another direct acting antiviral such as the investigational drug daclatasvir or Olysio (simeprevir) and also treating arrhythmia with amiodarone are at serious risk of developing symptomatic bradycardia. This dangerous combination has already resulted in one patient death due to cardiac arrest and